Funded Artificial Intelligence Startups in Boston
Boston's AI startup ecosystem spans a wide range of funded companies across these 50 rows, with round dates running from August 2023 through November 2025.
Boston's AI startup ecosystem spans a wide range of funded companies across these 50 rows, with round dates running from August 2023 through November 2025. Health and life sciences applications account for a notable share — Beacon Biosignals ($86M Series B, November 2025), AI Proteins ($42M Series A, November 2025), Cascala Health ($9M Seed), Rhino Health ($15M Series A), and DeepCure ($25M Series A) all closed rounds within this window, reflecting the city's deep life sciences infrastructure.
Infrastructure and enterprise AI are also well-represented. Lightmatter raised a $400M Series D in October 2024 — the largest disclosed round in the dataset — while CloudZero ($56M Series C, May 2025) and Gradient AI ($56M Series C, July 2024) each crossed the $50M threshold. Stage distribution runs broadly from pre-seed raises like HYBRD ($500K) and Copley ($5M) through late-stage growth capital, with roughly a dozen rounds carrying undisclosed amounts across Series Unknown and Venture - Series Unknown classifications.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Boston AI startups in this dataset?
Lightmatter leads at $400M (Series D, October 2024), followed by Caresyntax at $100M and Beacon Biosignals at $86M (Series B, November 2025). CloudZero and Gradient AI each raised $56M Series C rounds, while Maven AGI closed a $50M Series B in June 2025.
How concentrated is health and life sciences AI in Boston's recent funding activity?
A substantial share of the companies listed operate in health or biotech applications — including Beacon Biosignals, AI Proteins, Rhino Health, Cascala Health, DeepCure, Marigold Health, KAID Health, SOPHiA GENETICS, and 1910 Genetics, among others. This density reflects Boston's established life sciences infrastructure and proximity to major academic medical centers.
How many of these rounds have undisclosed amounts?
Approximately 12 of the 50 rounds carry undisclosed amounts, including SOC Prime, Indico Data, Cogito, Flexxbotics, and AirWorks. Undisclosed figures are concentrated in the Venture - Series Unknown and Series Unknown classifications.
Which funding stages appear most frequently in this group?
Series Unknown and Venture - Series Unknown rounds together account for the largest share of entries. Seed-stage rounds number at least nine, including Agency AI ($12M), Cascala Health ($9M), and Biometry ($5M). Pre-seed activity is also present across five companies, ranging from Copley ($5M) down to HYBRD ($500K).
How recent is the funding activity shown, and does it skew toward any particular period?
The two most recent rounds date to November 2025 — AI Proteins (Series A, $42M, November 22) and Beacon Biosignals (Series B, $86M, November 15). Activity is spread across mid-2023 through late 2025, with 2024 contributing the largest share of the 50 rows shown.
Are there Boston AI companies in this dataset focused on cybersecurity or enterprise security?
Three companies in the dataset target AI-driven security use cases: SOC Prime (Venture - Series Unknown, November 2025), Enkrypt AI (Seed, $2M, February 2024), and Cyberknight (Pre-Seed, undisclosed, October 2023).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.